Gremubamab

Names

[ Name ]:
Gremubamab

Biological Activity

[Description]:

Gremubamab (MEDI3902) is a humanized IgG1 kappa anti-PcrV/Psl monoclonal antibody. Gremubamab binds to the PA PcrV protein and Psl exopolysaccharide. Gremubamab has the potential for the research of pseudomonas aeruginosa infections[1][2].

[Related Catalog]:

Research Areas >> Infection

Signaling Pathways >> Anti-infection >> Bacterial

[In Vivo]

Gremubamab (1, 5, 15 mg/kg; i.v.; at 1 h postinfection) 改善兔急性肺炎模型的生存结果[2]。 Animal Model: Rabbits (acute pneumonia model)[2] Dosage: 1, 5, 15 mg/kg Administration: I.v.; at 1 h postinfection Result: Improved survival outcomes in a dose-dependent manner in a rabbit acute pneumonia model.

[References]

[1]. Chastre J, et al. Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial. Crit Care. 2022 Nov 15;26(1):355.

[2]. Le HN, et al. Treatment Efficacy of MEDI3902 in Pseudomonas aeruginosa Bloodstream Infection and Acute Pneumonia Rabbit Models. Antimicrob Agents Chemother. 2019 Jul 25;63(8):e00710-19.

Chemical & Physical Properties

No Any Chemical & Physical Properties